Macfarlanes advises Charterhouse Capital Partners on acquisition of Phastar

12 January 2021

Macfarlanes has advised private equity firm Charterhouse Capital Partners on the tax aspects of its acquisition of Phastar, a specialist provider of biostatistics and data science services for clinical trials.

Phastar is a fast growing, specialist biometrics clinical research organisation (CRO) offering statistical consulting, clinical trial reporting, data science and data management services to a global customer base of large and mid-size pharmaceutical companies.

Charterhouse Capital Partners will support Phastar’s existing management team with their approach for building the leading global, specialised biostatistics CRO through continued investment in the business as well as selective expansion into different markets. 

The Macfarlanes team was led by tax and reward partner Peter Abbott with assistance from tax director Gary Stokes and senior solicitor Laura Foley.